Publication: Long term follow-up of international randomised phase 3 study of rituximab versus a watch and wait approach for patients with asymptomatic, low tumour burden follicular lymphoma shows rituximab is highly effective at delaying time to new treatment without detrimental impact following next line of therapy
dc.contributor.coauthor | Northend, Michael | |
dc.contributor.coauthor | Wilson, William | |
dc.contributor.coauthor | Clifton-Hadley, Laura | |
dc.contributor.coauthor | Rana, Zaynab | |
dc.contributor.coauthor | Martin, Tanya-Louise | |
dc.contributor.coauthor | Young, Moya | |
dc.contributor.coauthor | Miall, Fiona | |
dc.contributor.coauthor | Cunningham, David | |
dc.contributor.coauthor | Walewski, Jan | |
dc.contributor.coauthor | Johnston, Amanda | |
dc.contributor.coauthor | Seymour, John F. | |
dc.contributor.coauthor | Linch, David C. | |
dc.contributor.coauthor | Ardeshna, Kirit M. | |
dc.contributor.department | N/A | |
dc.contributor.kuauthor | Ferhanoğlu, Ahmet Burhan | |
dc.contributor.kuprofile | Faculty Member | |
dc.contributor.schoolcollegeinstitute | School of Medicine | |
dc.contributor.yokid | 18320 | |
dc.date.accessioned | 2024-11-09T23:07:47Z | |
dc.date.issued | 2022 | |
dc.description.abstract | N/A | |
dc.description.indexedby | WoS | |
dc.description.openaccess | YES | |
dc.description.publisherscope | International | |
dc.description.volume | 140 | |
dc.identifier.doi | 10.1182/blood-2022-156790 | |
dc.identifier.eissn | 1528-0020 | |
dc.identifier.issn | 0006-4971 | |
dc.identifier.quartile | Q1 | |
dc.identifier.uri | http://dx.doi.org/10.1182/blood-2022-156790 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/9203 | |
dc.identifier.wos | 893223201193 | |
dc.keywords | N/A | |
dc.language | English | |
dc.publisher | American Society of Hematology (ASH) | |
dc.source | Blood | |
dc.subject | Hematology | |
dc.title | Long term follow-up of international randomised phase 3 study of rituximab versus a watch and wait approach for patients with asymptomatic, low tumour burden follicular lymphoma shows rituximab is highly effective at delaying time to new treatment without detrimental impact following next line of therapy | |
dc.type | Meeting Abstract | |
dspace.entity.type | Publication | |
local.contributor.authorid | 0000-0002-4257-549X | |
local.contributor.kuauthor | Ferhanoğlu, Ahmet Burhan |